Immunovant
IMVT
181 hedge funds and large institutions have $2.26B invested in Immunovant in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 74 increasing their positions, 64 reducing their positions, and 35 closing their positions.
226% more call options, than puts
Call options by funds: $71.2M | Put options by funds: $21.8M
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
16% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 64
14% more capital invested
Capital invested by funds: $1.97B → $2.26B (+$285M)
2.96% more ownership
Funds ownership: 51.14% → 54.1% (+3%)
8% less funds holding
Funds holding: 197 → 181 (-16)
46% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$60.6M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$50.3M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$43.2M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$33.7M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$22.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$23.9M |
| 2 |
CC
Commodore Capital
New York
|
-$19.8M |
| 3 |
FTM
First Turn Management
Del Mar,
California
|
-$18.4M |
| 4 |
FAM
Fred Alger Management
New York
|
-$16M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$12M |
IMVT Hedge Fund Activity: Q3 2024 in Review
181 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q3 2024, worth a combined $2.26B — up 14% from $1.97B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of IMVT and 19 opened new positions — a net loss of 16 holders — while 64 trimmed existing stakes and 74 added.
The largest buyer was Fidelity Investments, adding an estimated $60.6M. The largest seller was Avidity Partners Management, cutting an estimated $23.9M.
- 181 institutional investors held Immunovant (IMVT) as of Q3 2024, down from 197 in Q2 2024.
- Funds reported $2.26B of Immunovant stock for Q3 2024, up 14% quarter-over-quarter.
- 19 funds opened new Immunovant positions in Q3 2024 and 35 closed out, a net change of -16 holders.
- The largest Immunovant buyer in Q3 2024 was Fidelity Investments, an estimated $60.6M added.
- The largest Immunovant seller in Q3 2024 was Avidity Partners Management, an estimated $23.9M sold.
Based on aggregated 13F filings for Q3 2024.